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The upper midwestern United States, which includes the region surrounding La Crosse, Wisconsin, is a well-de-
scribed focus of Ixodes scapularis ticks. As a result, annual 
incidence of Lyme disease has been high (1) and prevalence 
of human granulocytic anaplasmosis (2) and babesiosis has 
been increasing (3). At the Gundersen Health System in La 
Crosse, we therefore use multiple laboratory procedures to 
screen patients with suspected I. scapularis tick–associ-
ated illness; the procedures include a whole-cell Borrelia 
burgdorferi ELISA and Western blot for confirming Lyme 
disease and PCRs for detecting infection with Anaplasma 
phagocytophilum or Babesia microti. However, other hu-
man illnesses caused by pathogenic microorganisms trans-
mitted from I. scapularis ticks continue to emerge. Primary 
among them is Borrelia miyamotoi (4), a spirochete bac-
terium that colonizes blood and typically causes relapsing 
fevers accompanied by chills, headache, fatigue, myalgia, 
arthralgia (5–8), and (rarely) meningoencephalitis (9).
The first case of human infection with B. miyamotoi was 
documented in 2011 in a patient from Russia (5); additional 
cases have since been detected in Russia, Europe, Asia, and 
the United States (7–11). Although cases seem to have oc-
curred only in patients who contracted the organism from 
infected I. scapularis ticks in the northeastern United States 
(8,10,11), persons in the upper midwestern United States 
(upper Midwest) are also commonly bitten by these ticks. In 
addition, Hamer et al. (12) detected B. miyamotoi DNA in I. 
scapularis ticks that had been captured from several sites in 
the upper Midwest during the 2006 and 2007 tick-questing 
seasons. We therefore conducted a retrospective investiga-
tion to determine whether patients at our healthcare facility 
with clinically suspected illness caused by tick bite could be 
infected with B. miyamotoi. To do so we also conducted B. 
miyamotoi DNA testing on blood samples submitted for A. 
phagocytophilum or B. microti DNA testing.
The Study
A total of 2,150 DNA samples were obtained from blood of 
patients evaluated during 2014–2015 for illness and tested 
for either A. phagocytophilum or B. microti because of clin-
ical complaints or abnormalities suggestive of tickborne ill-
ness. Because our current laboratory procedures for con-
firming either infection require extraction of DNA from a 
blood sample before PCR testing, we also evaluated the 
extracted DNA for B. miyamotoi. Ethics approval for de-
tecting and sequencing unique bacterial DNA from routine 
clinical samples and linkage to patient data without indi-
vidual informed consent was obtained from the Gundersen 
Institutional Review Board with the stipulation that patient 
identifiers be appropriately redacted and information be 
used only as surveillance data for public health purposes.
We initially screened the DNA samples with a modi-
fication of a previously described B. miyamatoi screening 
PCR (13), which amplified a 70-bp DNA fragment of the 
16S ribosomal RNA gene specific for B. miyamatoi. In 
brief, we combined 5 μL of extracted DNA with 20 μL of 
a master mix that contained 12.5 μL of buffer (AmpliTaq 
Gold DNA Polymerase with GeneAmp 10X PCR Gold 
Buffer; Life Technologies, Austin, TX, USA); 2.5 mmol/L 
magnesium chloride, deoxynucleoside triphosphates; 
7 μL of a primer/probe mix comprising forward primer 
5′-GCTGTAAACGATGCACACTTGGT-3′, reverse prim-
er 5′-GGCGGCACACTTAACACGTTAG-3′, and probe 
5′-HEX-CGGTACTAACCTTTCGATTA-3′; and 0.5 μL 
(1.5 U) AmpliTaq Gold DNA Polymerase under the fol-
lowing conditions: 1 cycle at 95°C for 10 min, 45 cycles 
at 95°C for 15 s, 63°C for 1 min, and a final cycle at 25°C 
for 5 s. For a positive control, we used strain HS1 (ATCC 
35209) of Borrelia hermsii because B. miyamotoi DNA or 
viable spirochetes are not easily obtained.
We amplified B. miyamotoi DNA from 7 patients (1 
male, 6 female) whose previous anaplasmosis and babe-
siosis test results were negative. Mean patient age was 51 
years (range 3–70 years), and 3 patients confirmed that 
they had been bitten by a tick suspected to be I. scapularis 
within the 10 days before becoming ill. The patients also 
resided in or near La Crosse; although none reported recent 
travel outside the region, we cannot rule out the possibility 
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that the infections were acquired elsewhere. Further sup-
porting local acquisition, however, we also recently detect-
ed B. miyamotoi DNA by the PCR used in this study in a 
small number (≈2%) of I. scapularis ticks collected locally 
(data not shown).
The clinical signs and symptoms strongly supported 
PCR positivity for B. miyamotoi (5–8). The most com-
mon clinical sign was fever; 1 patient reported additional 
episodes of fever during the 2 months before seeking treat-
ment (Table). In addition, skin lesions were not detected, 
although 1 patient may have been co-infected with B. burg-
dorferi; an IgM Western blot test performed in the clinical 
laboratory also yielded reactivity sufficient to provide sero-
diagnostic confirmation of early Lyme disease (14). More-
over, elevated levels of serum alanine aminotransferase (n 
= 2) or aspartate aminotransferase (n = 1) were detected in 
the only 2 patients for whom B. miyamotoi DNA was iden-
tified and who were tested for these liver enzyme abnor-
malities. In addition, the infected patients received doxycy-
cline therapy for at least 7 days (mean 10 days; range 7–14 
days), which uniformly resulted in complete resolution of 
clinical signs and symptoms.
For final confirmation of infection with B. miyamotoi, 
we then reamplified a 142-bp fragment (bp 636–777) of 
the glycerophosphodiester phosphodiesterase (glpQ) gene 
from the remaining DNA sample from each patient posi-
tive for B. miyamotoi by PCR. The glpQ gene was targeted 
because the GlpQ protein is absent in the Borrelia species 
that cause Lyme disease (15), which are detected rela-
tively frequently in patients from the region (1). In brief, 
5 μL of DNA was combined with 20 μL of a master mix 
that contained 12.5 μL of buffer, 0.5 µmol/L of forward 
(5′-GATAATATTCCTGTTATAATGC-3′) and reverse 
(5′-CACTGAGATTTAGTGATTTAAGTTC-3′) primers, 
and 0.5 μL (1.5 U) of AmpliTaq Gold DNA polymerase. 
The DNA was then amplified under the following condi-
tions: 1 cycle at 95°C for 3 min followed by 50 cycles at 
95°C for 45 s, 56°C for 30 s, and 72°C for 60 s, followed 
by a final extension at 72°C for 7 min. Amplified material 
was purified (QIAquick PCR Purification Kit; QIAGEN, 
Hilden, Germany) and forwarded to Laragen Inc. (Culver 
City, CA, USA) for sequencing. In each instance, the se-
quence of the amplified fragment was 100% homologous 
with that of B. miyamotoi LB-2001 (GenBank accession 
no. CP006647.2).
Conclusions
Researchers have documented human illness caused by B. 
miyamotoi transmitted from I. scapularis ticks (5,7–9,11), 
but infections in patients from the United States have to date 
been described only for residents of the northeastern part 
of the country (10). In this study, however, we confirmed 
characteristic illness caused by infection with B. miyamotoi 
in 7 patients who resided in the I. scapularis tick–endemic 
focus surrounding La Crosse, Wisconsin. Given these find-
ings, clinicians in the upper Midwest must now also con-
sider the possibility of B. miyamotoi infection in patients 
with suspected tickborne illness, especially because even 
more cases will probably be detected as appropriate meth-
ods, such B. miyamotoi-specific anti-GlpQ antibody test-
ing (8,15) or B. miyamotoi DNA detection, become more 
widely available. Studies to provide additional insight into 
human infection with B. miyamotoi remain necessary be-
cause the prevalence of the illness will probably increase 
even more as I. scapularis ticks continue to disperse.
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